Investigating the phase-solubility and compatibility study of anticancer drug complexed with β-cyclodextrin and HP–β-cyclodextrin

Abstract

Poor  aqueous  solubility  and  dissolution  rates  are  critical  problems  that  hinders  the  formulation, development  and  delivery  of  most  of  BCS  class  II  and  class  IV  drugs.  Gefitinib  is  a  cytotoxic chemotherapeutic  drug  used  in  treatment  of  cancer.    The  objective  of  the  present  study  was  to investigate  the  drug-cyclodextrin  compatibility  study  by  FTIR  and  DSC  study.  The  phase solubility  study  revealed  formation  of  1:1  stoichiometry  binary  inclusion  complex.  The  complex was  prepared  by  kneading  method.  FT-IR  spectra  provided  the  data  indicating  that  the  HP-β-CD was  more  effective  than  β-CD.  Differential  scanning  calorimetry  thermograms  indicated  stronger amorphization and entrapment of  gefitinib with HP-β-CD.